Purpose: Intravenous administration of the antiseizure medication lacosamide can be delayed given operational challenges related to short beyond-use-dating and controlled substance requirements. The purpose of this study was to describe the steps required to successfully transition from intravenous piggyback administration to intravenous push administration and demonstrate that workflow changes improved time to administration without compromising patient safety.
Methods: This multicenter study had 2 components; the first portion was a prospective description of the implementation and operationalization process, while the second was a retrospective cohort analysis comparing patients who received intravenous piggyback and intravenous push lacosamide. After the transition, the default administration route for adult patients for lacosamide doses of 400 mg or less was intravenous push. While the primary objective was to describe the implementation process, secondary objectives included comparison of time to administration and safety, using a composite and incidence of PR prolongation.
Results: Success in implementation and operationalization across a large health system was achieved by following a 6-month timeline. A total of 102 patients were included in the cohort study, with 869 individual administrations analyzed (519 intravenous piggyback and 350 intravenous push). Time from verification to administration was significantly decreased when comparing intravenous piggyback (median, 159 minutes) to intravenous push (median, 88 minutes) administrations (P = 0.008). No significant difference was found in the safety composite or PR prolongation.
Conclusion: Transitioning intravenous lacosamide administration from piggyback to push administration is feasible and decreases time from verification to administration without increased incidence of adverse effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajhp/zxae202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Short Course of Standard Velcade/Dexamethasone Followed by Unlimited Weekly Maintenance Therapy Is an Effective Treatment in Relapsed/Refractory Multiple Myeloma.
Cancers (Basel)
November 2024
Herbert-Herman Cancer Center, University of Michigan Health-Sparrow, Lansing, MI 48912, USA.
Background: Bortezomib (B), known as Velcade, is a reversible proteasome inhibitor approved for relapsed/refractory multiple myeloma (RRMM) patients (pts). The standard of care protocol includes eight cycles of intravenous push (IVP) injections of B and oral dexamethasone (D), which increases the toxicity. Here, we describe the results of an open-label, phase II clinical trial employing only four cycles of B/D.
View Article and Find Full Text PDFEvidence-based obstetric guidance in the setting of a global intravenous fluid shortage.
Am J Obstet Gynecol MFM
December 2024
Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of North Carolina, Chapel Hill, NC (Heerboth, Trawick, Coviello, and Quist-Nelson).
Intravenous fluid (IVF) administration is a ubiquitous medical intervention. Although there are clear benefits to IVF in certain obstetric scenarios, IVF is often given in unindicated circumstances; the ongoing IVF shortage highlights an opportunity to reduce unindicated IVF in obstetrics. This document provides evidence-based recommendations to reduce IVF use within general obstetric practice.
View Article and Find Full Text PDFEvaluation of the Efficacy of Intravenous Push and Intravenous Piggyback Ceftriaxone in Critically Ill Patients.
Antibiotics (Basel)
September 2024
Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens, GA 30602, USA.
: Intravenous fluid shortages have led to fluid-sparing measures such as intravenous push (IVP) administration of antibiotics. This study aimed to compare the safety and efficacy of IVP and intravenous piggyback (IVPB) ceftriaxone in critically ill patients. : Demographics were similar in IVP ( = 201) and IVPB ( = 200) groups.
View Article and Find Full Text PDFAssessing the Costs of Intravenous Push Waste in Intraoperative Areas Through Observation: A Multi-site Study.
Drugs Real World Outcomes
December 2024
Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA.
Article Synopsis
- The study addresses the high costs of managing and disposing of controlled substances in healthcare, especially in light of the opioid crisis and the need for safe disposal practices.
- It involves a multi-site observational analysis of waste from substances like fentanyl, hydromorphone, morphine, midazolam, and ketamine, comparing automated and non-automated disposal workflows.
- Results showed significant costs related to both pharmaceutical waste and workforce time, with an estimated annual waste cost of $56,557 for two hospitals, highlighting the financial impact of controlled substance disposal.
Infusion parameters, safety, and practical guidance for the manual administration of subcutaneous immunoglobulin 20% (Ig20Gly).
Allergy Asthma Clin Immunol
October 2024
Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Article Synopsis
- Primary immunodeficiency diseases (PIDs) are genetic immune system disorders requiring lifelong immunoglobulin replacement therapy, usually delivered through IVIG or SCIG infusions.
- Ig20Gly, a 20% immune globulin solution, is a replacement therapy approved for various age groups, with recent approvals for manual administration in Europe aimed at simplifying the process.
- Manual administration of Ig20Gly allows for faster infusion rates, similar safety and satisfaction levels compared to infusion pumps, and potential cost savings for healthcare systems due to lower equipment and nursing needs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!